«This study demonstrates that Prosigna can reliably identify early stage breast cancer patients who have a low risk -
of disease recurrence at 10 years, including a substantial proportion
of patients with node - positive disease for whom the risk /
benefit derived for
adjuvant chemotherapy would be at best neutral,» said Dr. Alessandra Cesano, chief medical officer
of NanoString Technologies.
This signature allows the identification
of those patients who have a high risk
of developing metastasis and who, therefore, might
benefit from
adjuvant chemotherapy.